ELDN - NASDAQ

Eledon Pharmaceuticals, Inc.

ELDN·NASDAQ

$3.53

+6.0%

HealthcareBiotechnology

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$211.62M

EPS-0.5600

P/E Ratio-2.71

Earnings Date08/06/2026

-62.34M

Operating Cash Flow

32%

3Y+119.0%

5Y+310.0%

10Y+71.0%

10.79M

Investing Cash Flow

-115%

3Y-

5Y-2.0%

10Y-70.0%

53.81M

Financing Cash Flow

-60%

3Y-

5Y-51.0%

10Y+145324.0%

Eledon Pharmaceuticals, Inc. Cash Conversion Engine

ELDN · NASDAQ

FCF Components

Net Income-45.62M

Depreciation & Amortization0.00

Stock-Based Compensation10.45M

Change in Working Capital7.65M

Others-34.83M

Capital Expenditures0.00

Free Cash Flow-62.34M

Cash Flow Quality Analysis

FCF Conversion Rate

136.7%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

FCF Growth Trend

-31.9%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$7.65M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Eledon Pharmaceuticals, Inc. Cash Flow Statement

ELDN • NASDAQ

Eledon Pharmaceuticals, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
OPERATING ACTIVITIES
Net Income	-45.6M	-36.2M	-116.5M	-88M	-34.5M	-22.8M	-16M	-14.1M	-13.1M	-38M	-45.1M	-23.3M	-15.7M	-9.6M
Depreciation & Amortization	0.0	359K	374K	373K	195K	183K	182K	11K	22K	171K	109K	21K	10K	9K
Change in Deferred Taxes	5K	431K	0.0	0.0	-2.4M	-404K	0.0	0.0	0.0	352K	72K	0.0	-238K	-210K
Stock-Based Compensation	10.5M	13.1M	6.5M	8.2M	7.9M	3.2M	1.3M	1.5M	579K	3M	2.9M	2.1M	238K	210K
Other Non-Cash Items	-34.8M	-33.7M	75M	48.6M	0.0	4.8M	1.9M	471K	49K	-2K	-235K	-158K	238K	210K
Change in Working Capital	7.7M	8.7M	-4.9M	2.4M	-152K	-180K	-1.2M	618K	-2.5M	-2.1M	1M	204K	1K	97K
Cash from Operating Activities	-62.3M	-47.3M	-39.5M	-28.4M	-28.9M	-15.2M	-13.9M	-11.9M	-14.9M	-36.5M	-41.2M	-21.1M	-15.5M	-9.3M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-17K	-565K	-25K	-23K	-8K
Acquisitions, Net	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(11M)	(0.0)	(0.0)	(23.3M)	-2K	(0.0)	(0.0)	(0.0)	(0.0)
Purchase of Investments	-161.1M	-156.1M	-78.3M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-500K	-39.9M	(0.0)	(0.0)	(0.0)
Sale/Maturity of Investments	171.9M	85.8M	33M	0.0	0.0	0.0	0.0	0.0	0.0	36.2M	0.0	0.0	0.0	0.0
Other Investing Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8K	2K	-70K	-150K	-30K	0.0
Cash from Investing Activities	(10.8M)	-70.3M	-45.3M	(0.0)	(0.0)	(11M)	(0.0)	(0.0)	(23.3M)	(35.7M)	-40.5M	-175K	-53K	-8K
FINANCING ACTIVITIES
Net Issuance of Common Stock	53.8M	133.3M	33M	0.0	-449K	9M	9.7M	7.5M	4.8M	0.0	0.0	97.9M	0.0	0.0
Net Issuance of Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M	0.0	0.0	0.0	0.0
Cash Paid for Dividends	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-25K	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Share Repurchases	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-25K	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Other Financing Items	0.0	215K	0.0	0.0	0.0	5.4M	0.0	71K	3.1M	0.0	513K	-3.1M	185K	4K
Cash from Financing Activities	53.8M	133.5M	33M	0.0	-449K	109.6M	9.7M	7.6M	7.9M	37K	513K	94.8M	35.6M	18.8M
CASH FLOW SUMMARY
Net Change in Cash	2.3M	15.9M	-51.8M	-28.4M	-29.4M	105.4M	-4.2M	-4.3M	16.2M	-800K	-81.2M	73.5M	20.1M	9.4M
Cash at Beginning of Period	20.5M	4.6M	56.4M	84.8M	114.2M	8.8M	13M	17.3M	1.1M	24M	105.3M	31.8M	11.7M	2.3M
Cash at End of Period	22.8M	20.5M	4.6M	56.4M	84.8M	114.2M	8.8M	13M	17.3M	23.2M	24M	105.3M	31.8M	11.7M
Free Cash Flow	-62.3M	-47.3M	-39.5M	-28.4M	-28.9M	-15.2M	-13.9M	-11.9M	-14.9M	-36.5M	-41.8M	-21.1M	-15.5M	-9.3M

SEC Filings

ELDN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
S-3 S-3 N/A	May 01, 2026	May 01, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2025 N/A	January 02, 2026	December 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 12, 2025	2025	View Filing

Showing 1 to 10 of 202 filings

Related Guides

Blog Categories

Continue your ELDN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.